Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Chronic Lymphocytic Leukemia News

News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
News
Measurable Residual Disease as a Treatment Guide for Patients with Chronic Lymphocytic Leukemia
01/30/2024

By Emry Lloyd

By Emry Lloyd
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.
In a recent study, Talha Munir,...
01/30/2024
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways

Advertisement

News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
News
Racial Differences in Ibrutinib Treatment Outcomes in Patients With CLL: A Real-World Analysis
11/28/2023

Edited by Emry Lloyd

Edited by Emry Lloyd
Study on real-world data on patients with chronic lymphocytic leukemia investigated the outcomes for both Black and White patients.
Study on real-world data on patients with chronic lymphocytic leukemia investigated the outcomes for both Black and White patients.
Study on real-world data on...
11/28/2023
Journal of Clinical Pathways
News
A Deeper Look Into Hypertension and Cardiovascular Toxicity Symptoms for Patients Treated With Ibrutinib
10/13/2023

Emry Lloyd

Emry Lloyd
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues evaluated the long-term effects in patients with chronic lymphocytic leukemia who reported hypertension or cardiovascular issues while receiving ibrutinib.
Max Gordon, MD, and colleagues...
10/13/2023
Journal of Clinical Pathways

Advertisement

News
Analysis of Outcomes for Patients With CLL Disease Progression While on Ibrutinib
09/14/2023

Emry Lloyd

Emry Lloyd
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis, researchers investigated the factors that contribute to worse outcomes for patients with CLL who experience disease progression while on ibrutinib.
In a recent analysis,...
09/14/2023
Journal of Clinical Pathways
News
Analysis of the Impact Bruton Tyrosine Kinase Inhibitor Discontinuation Has After First- or Second-Line Therapy
08/22/2023

Emry Lloyd

Emry Lloyd
Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.
Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.
Researchers studied data on the...
08/22/2023
Journal of Clinical Pathways
News
Study Analyzes Trends in Medicare Spending on Oral Drugs for Chronic Lymphocytic Leukemia From 2014 to 2020
05/11/2023

Grace Taylor

Grace Taylor
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, and colleagues recently evaluated...
Edward R. Scheffer Cliff, MBBS,...
05/11/2023
Journal of Clinical Pathways

Advertisement

News
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
04/24/2023

Gina Tomaine

Gina Tomaine
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...
On January 19, 2023, the Food and Drug Administration (FDA) approved zanubrutinib for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This approval was based on the SEQUOIA and ALPINE trials, respectively. The...
On January 19, 2023, the Food...
04/24/2023
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use